Skip to content

Checked

Class IDrug recallOngoing

DOXOrubin Hydrochloride Liposome injection recall

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC of Princeton, NJ · FDA report 06/17/2026

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class I
Most serious
Status
Ongoing
Recall started
05/12/2026
Distribution
Nationwide

Reason for recall

Presence of Particulate matter: Particulate matter identified as glass.

Class I: A reasonable chance that using or being exposed to the product will cause serious health problems or death.

Recalled product

Product
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, NDC 72603-200-01.
Lot and code info
Lot HAG2581B, expires: 05/31/2027
Quantity
675 vials
Brand names
DOXORUBICIN HYDROCHLORIDE
Recall number
D-0580-2026
Event ID
98921
Initiated by
Voluntary: Firm initiated

Where it was distributed

U.S. Nationwide

  • Nationwide

Recall timeline

  1. 05/12/2026Firm started the recall
  2. 06/05/2026FDA classified it as Class I
  3. 06/17/2026Published in the FDA enforcement report

More recalls from SUN PHARMACEUTICAL INDUSTRIES

Frequently asked questions

Why was DOXOrubin Hydrochloride Liposome injection recalled?
Presence of Particulate matter: Particulate matter identified as glass.
What does Class I mean?
Class I is FDA's most serious recall category: a reasonable chance that using or being exposed to the product will cause serious health problems or death.
Where was the recalled product sold?
U.S. Nationwide
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 06/17/2026 · Do not rely on openFDA to make decisions regarding medical care